Here's the genuine response: VIP is not really a common-goal anti-inflammatory peptide you may substitute into any protocol anticipating broad immune suppression. Its effects are receptor-particular, tissue-dependent, and timing-sensitive in ways that make protocol layout noticeably more complicated